Diabetes in the next century: Challenges and opportunities

Netherlands Journal of Medicine

Volumn 55, Issue 6, 1999, Pages 265-270

  Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; INSULIN; NEW DRUG;

ARTICLE; FUTUROLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; NETHERLANDS;

EID: 0032700527     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00092-3     Document Type: Article

References (29)

1. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197.
2. Krans H.M.J. Diabetes mellitus: nieuwe classificatie naar oorzaak en aangescherpte bloedglucosewaarden voor diagnostiek. Ned Tijdsch Geneeskd. 142:1998;225-229.
3. Stolk R.P., De Vegt F., Heine R.J. Wat zijn de gevolgen van nieuwe Amerikaanse richtlijnen voor de diagnostiek van diabetes mellitus voor Nederland. Ned Tijdsch Geneeskd. 142:1998;222-225.
4. Heine R.J. Prevention strategies: the use of drugs. Hitman G.A. Type 2 diabetes; prediction and prevention. 1999;283-302 Wiley, Chichester.
5. Ruwaard D., Hirasing R.A., Reeser H.M., et al. Increase in incidence of type 1 (insulin dependent) diabetes mellitus in the Netherlands: the second nationwide study among children under 20 years of age. Diabetes Care. 17:1994;599-601.
6. Akerblom H.K., Knip M. Putative environmental factors in type 1 diabetes. Diabetes Metab Rev. 14:1998;31-67.
7. Efrat S. Prospects for gene therapy of insulin-dependent diabetes mellitus. Diabetologia. 41:1998;1401-1409.
8. Zimmet P., Lefebvre P. The global NIDDM pandemic. Treating the disease and ignoring the symptoms. Diabetologia. 39:1996;1247-1248.
9. De Courten M., McCarty D., Zimmet P. Diagnosis: the scale of the problem and future risks. Hitman G.A. Type 2 diabetes; prediction and prevention. 1999;17-36 Wiley, Chichester.
10. Mooy J.M., Grootenhuis P.A., De Vries H., et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: The Hoorn Study. Diabetes Care. 18:1995;1270-1274.
11. Heine R.J., Mooy J.M. Impaired glucose tolerance and unidentified diabetes. Postgrad Med J. 72:1996;67-72.
12. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc. 281:1999;1291-1297.
13. Haffner S.M., Miettinen H., Stern M.P. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia. 40:1997;711-717.
14. Herman W.H., Eastman R.C. The effect of treatment on the direct costs of diabetes. Diabetes Care. 21:(suppl 3):1998;C19-28.
15. Hales C.N., Barker D.J.P., Clark P.M.S., Cox L.J., Fall C., Osmond C., Winter P.D. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J. 303:1991;1019-1022.
16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 329:1993;977-986.
17. UK Prospective Diabetes Study 33: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 352:1998;837-853.
18. Snoek F.J., van der Ven N.C.W., Lubach C. Cognitive Behavioural Group Training for poorly controlled type 1 diabetic patients - a psychoeducational approach. Diabetes Spectrum. 12:1999;147-152.
19. Rubin R.J., Dietrich K.A., Hawk A.D. Clinical and economic impact of implementing a comprehensive diabetes management programme in managed care. J Clin Endocrinol Metab. 83:1998;2635-2642.
20. Wahren J., Ekberg K., Fernqvist-Forbes E., Nair S. Brain substrate utilisation during acute hypoglycemia. Diabetologia. 32:1999;812.
21. Kanc K., Janssen M.M.J., Keulen E.J.P., Jacobs M.A.J.M., Popp-Snijders C., Snoek F.J., Heine R.J. Substitution of night time continuous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia. 41:1998;322-329.
22. Wolffenbuttel B.H.R., Heine R.J. Kortwerkende insuline analoga. Ned Tijdschr Geneeskd. 142:1998;397-400.
23. Albisser A.M., Leibel B.S., Ewart T.G., et al. Clinical control of diabetes by the artificial pancreas. Diabetes. 23:1974;397-404.
24. Feener E.P., King G.L. Vascular dysfunction in diabetes mellitus. Lancet. 350:(suppl 1):1997;9-13.
25. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Nat Acad Sci USA. 95:1998;4630-4634.
26. Tight blood pressure control and rise of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 317:1998;703-713.
27. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the CARE trial. Circulation. 98:1998;2513-2519.
28. Piwernetz K., Home P.D., Snorgaard O. Monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the diabetes care initiative. Diabetic Med. 10:1993;371-377.
29. de Sonnaville J.J.J., Bouma M., Colly L.P., Deville W., Wijkel D., Heine R.J. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2 year follow-up study. Diabetologia. 40:1997;1334-1340.